Arama Sonuçları - Kerstin Maria Kampa-Schittenhelm
- Gösterilen 1 - 4 sonuçlar arası kayıtlar. 4
-
1
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms Yazar: Kerstin Maria Kampa-Schittenhelm, Michael C. Heinrich, Figen Akmut, Hartmut Döhner, Konstanze Döhner, Marcus M. Schittenhelm
Baskı/Yayın Bilgisi 2013Artigo -
2
The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro Yazar: Matthias Krusch, Julia Salih, Manuela Schlicke, Tina Baessler, Kerstin Maria Kampa-Schittenhelm, Frank Mayer, Helmut R. Salih
Baskı/Yayın Bilgisi 2009Artigo -
3
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia Yazar: Kerstin Maria Kampa-Schittenhelm, Michael C. Heinrich, Figen Akmut, Katharina Henriette Rasp, Barbara Illing, Hartmut Döhner, Konstanze Döhner, Marcus M. Schittenhelm
Baskı/Yayın Bilgisi 2013Artigo -
4
N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence Yazar: Zhiping Wang, Yuangang Liu, Maho Takahashi, Kathryn Van Hook, Kerstin Maria Kampa-Schittenhelm, Brett C. Sheppard, Rosalie C. Sears, Philip A. Stork, Charles D. Lopez
Baskı/Yayın Bilgisi 2012Artigo
Arama Araçları:
İlgili Konular
Biochemistry
Biology
Cancer research
Cell biology
Immunology
Signal transduction
Cancer
Cell cycle
Kinase
Leukemia
Acute leukemia
Anti-apoptotic Ras signalling cascade
Apoptosis
Art
Cell
Cell growth
Chemistry
Dual (grammatical number)
Enzyme
GTP'
Gene
Genetics
Hepatocellular carcinoma
Immune system
In vitro
Internal medicine
Literature
MAPK/ERK pathway
Medicine
Oncogene